Paion AG (PA8) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Paion AG (PA8) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH63358D
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Paion AG (Paion) is a specialty pharmaceutical company that focuses on the development and commercialization of drugs used for out-patient and hospital-based sedation, anesthesia and critical care services. The company's lead product, remimazolam, is designed for the treatment of patients requiring sedation. Paion currently develops remimazolam for general anesthesia. The company completed clinical development program for general anesthesia in Japan and initiated a Phase 3 trial in the European Union. It has presence in the UK, the US and Germany. Paion is headquartered in Aachen, Germany.

Paion AG (PA8)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paion AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Paion AG, Medical Devices Deals, 2012 to YTD 2018 10

Paion AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Paion AG, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Paion Raises USD 4.8 Million In Venture Financing 12

Licensing Agreements 13

Mundipharma Enters into Licensing Agreement with Paion 13

Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14

Paion Enters into Licensing Agreement with Yichang Humanwell for M6G 15

Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 16

Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 17

Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 18

Paion Extends Licensing Agreement With R-Pharm For Remimazolam 19

Paion Exercises Option for Licensing Agreement with Hana Pharma for Remimazolam 20

Yichang Humanwell Pharma Exercises Option with Paion to License Remimazolam 21

Equity Offering 23

Paion to Raise USD6 Million in Private Placement of Shares 23

Paion Raises USD9.2 Million in Private Placement of Shares 24

Paion to Raise USD5.3 Million in Rights Offering 25

Paion Raises USD10.9 Million in Private Placement of Shares 26

Paion Raises USD5.4 Million in Private Placement of Shares 27

Paion Raises USD61.3 Million in Rights Offering of Shares 28

Paion Raises USD1.4 Million in Private Placement of Shares 29

Paion Completes Private Placement of Shares for USD8.5 Million 30

Paion Completes Private Placement Of Shares For USD 8.4 Million 31

Paion Completes Rights Offering of Shares for USD6.86 Million 32

Asset Transactions 33

Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 33

Paion AG-Key Competitors 35

Paion AG-Key Employees 36

Paion AG-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Aug 08, 2018: Paion reports financial results for the first half-year 2018 38

Mar 22, 2018: PAION reports on fiscal year and financial results 2017 41

Nov 08, 2017: Paion Publishes Group Quarterly Statement For The First Nine Months Of 2017 44

Aug 09, 2017: PAION reports financial results for the first half-year of 2017 47

Mar 16, 2017: PAION reports on fiscal year and financial results 2016 50

Product Approvals 53

Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required 53

Clinical Trials 54

Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

Paion AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paion AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Paion AG, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Paion AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paion AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paion AG, Deals By Therapy Area, 2012 to YTD 2018 9

Paion AG, Medical Devices Deals, 2012 to YTD 2018 10

Paion AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Paion Raises USD 4.8 Million In Venture Financing 12

Mundipharma Enters into Licensing Agreement with Paion 13

Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14

Paion Enters into Licensing Agreement with Yichang Humanwell for M6G 15

Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 16

Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 17

Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 18

Paion Extends Licensing Agreement With R-Pharm For Remimazolam 19

Paion Exercises Option for Licensing Agreement with Hana Pharma for Remimazolam 20

Yichang Humanwell Pharma Exercises Option with Paion to License Remimazolam 21

Paion to Raise USD6 Million in Private Placement of Shares 23

Paion Raises USD9.2 Million in Private Placement of Shares 24

Paion to Raise USD5.3 Million in Rights Offering 25

Paion Raises USD10.9 Million in Private Placement of Shares 26

Paion Raises USD5.4 Million in Private Placement of Shares 27

Paion Raises USD61.3 Million in Rights Offering of Shares 28

Paion Raises USD1.4 Million in Private Placement of Shares 29

Paion Completes Private Placement of Shares for USD8.5 Million 30

Paion Completes Private Placement Of Shares For USD 8.4 Million 31

Paion Completes Rights Offering of Shares for USD6.86 Million 32

Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For USD 27 Million 33

Paion AG, Key Competitors 35

Paion AG, Key Employees 36

Paion AG, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Paion AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com